Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Forest, AZ Collaborate on Antibiotic | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Forest, AZ Collaborate on Antibiotic

Forest Labs and AZ will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Forest Laboratories and AstraZeneca have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan. Ceftaroline is Forest’s late-stage, next generation cephalosporin being investigated for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). Ceftaroline demonstrates bactericidal activity against a broad range of pathogens commonly implicated in cSSSI and CABP, including methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP).

AZ will pay Forest an undisclosed upfront fee, sales-related royalties and payments for reaching certain sales milestones. AZ will assume responsibility for the development, regulatory approval and commercialization of ceftaroline in the licensed territory. The parties will collaborate on future development activities. Financial terms were not disclosed.

David Brennan, chief executive officer of AZ, remarked, “AstraZeneca and Forest Laboratories, through a successful partnership, aim to battle the growing problem of antibiotic resistance. This collaboration complements our existing antibiotic Merrem, and our significant investment in antibiotic research, as well as agents in development such as CytoFab. We are excited to be partnering with Forest and to be part of ceftaroline’s future.”

Forest expects to file an NDA in the U.S. by the end of 2009, while AZ plans to file an MAA in Europe by the end of 2010.

Read AstraZeneca’s profile in this year’s Top Companies report!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters